Irras AB is Sweden- based medical device company primarily engaged in develops and commercializes solutions that are designed to transform neurocritical care. Company focus on neurosurgical procedures, where excess cerebrospinal fluid (CSF) or toxic blood byproducts often need to be emergently drained and intracranial pressure (ICP) needs to be closely regulated.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company

Market Cap	18Cr 1.9Cr 1.65Cr 1.53Cr 1.43Cr 2.69Cr 179.01Cr 2.71Cr 7.04Cr 88Cr 7.12Cr 6.97Cr 305.95Cr	P/E 2023	-0.73x	P/E 2024	-1.89x
Enterprise Value	40Cr 4.13Cr 3.6Cr 3.33Cr 3.12Cr 5.85Cr 389.59Cr 5.89Cr 15Cr 191.76Cr 15Cr 15Cr 665.85Cr	EV / Sales 2023	5.26x	EV / Sales 2024	6.82x
Free-Float	3.55%	Yield 2023 *	-	Yield 2024	-

28/25/28	IRRAS AB Reports Earnings Results for the Full Year Ended December 31, 2024	CI
18/24/18	IRRAS AB Reports Earnings Results for the Full Year Ended December 31, 2023	CI
03/23/03	Irras has today its last day of trading on Nasdaq Stockholm before delisting	FW
24/23/24	IRRAS AB(OM:IRRAS) dropped from OMX Nordic All-Share Index	CI
24/23/24	IRRAS AB(OM:IRRAS) dropped from OMX Nordic Small Cap Index	CI
23/23/23	Irras Obtains Nasdaq Approval for Delisting in Stockholm	MT
20/23/20	Irras delisted from Nasdaq Stockholm with last trading day on November 3	FW
20/23/20	Sweden's Irras Files for Delisting as Privatization Nears Completion	MT
20/23/20	IR Holding Bidco calls for compulsory acquisition in Irras - applies for delisting	FW
16/23/16	Irras Obtains Extension for SEK20 Million Loan	MT
16/23/16	Irras extends SEK 20 million short-term loan	FW
02/23/02	Bidder controls 87.9 percent of the shares in Irras after completion of takeover bid	FW
19/23/19	Set-off issue only realistic option to avoid insolvency situation - Irra Board	FW

30/23/30	Bid for Irras below historical median premium - but also high risk of more fundraising - Afv(R)	FW
30/23/30	Bid for Irras below historical median premium - but also high risk of more fundraising - Afv	FW
22/23/22	Irra's Q1 sales below expectations - Redeye predicts new share issue and halves fair value	FW
22/23/22	Redeye lowers motivated value for Irras to SEK 0.15 (0.30)	FW
20/23/20	Redeye reiterates motivated value for Irras, but predicts capital raising this year	FW

20/23/20	IRRAS's application for delisting has been approved and the Board of Directors has resolved not to publish the interim report for the third quarter of 2023	AQ
20/23/20	NOTICE TO ATTEND THE EXTRAORDINARY GENERAL MEETING OF IRRAS AB	AQ
20/23/20	IR Holding Bidco Inc. requests compulsory buy-out and IRRAS applies for delisting	AQ
16/23/16	IRRAS publishes prospectus	AQ
16/23/16	IRRAS has extended maturity date for its SEK 20 million short-term loan	AQ

Manager	Title	Age	Since
Will Martin CEO	Chief Executive Officer	51	01/07/2021
Griffen Stapp DFI	Director of Finance/CFO	40	17/06/2021
Sten Gustafsson IRC	Investor Relations Contact	-	09/03/2021

IRRAS AB Share Price OTC Markets

Stocks

IRRA.F

SE0008321202

Medical Equipment, Supplies & Distribution

Valuation: IRRAS AB

Latest news : IRRAS AB

Analysts' recommendations: IRRAS AB

Press Releases: IRRAS AB

Quotes and Performance

Managers and Directors: IRRAS AB

Medical Devices & Implants

Financials

Company Profile

Director	Title	Age	Since
Kleanthis Xanthopoulos BRD	Director/Board Member	68	01/06/2015
Marios Fotiadis CHM	Chairman	53	18/08/2020
Inger Gunnel Anita Tollstadius BRD	Director/Board Member	71	01/09/2017

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
IRRAS AB	-15.36%	-27.68%	-	-	1.69Cr
STRYKER CORPORATION	+2.21%	-1.41%	-17.54%	+4.57%	12TCr
SMITH & NEPHEW PLC	-0.66%	-0.71%	+4.75%	-9.49%	1.27TCr
GLAUKOS CORPORATION	+2.57%	+3.05%	+27.69%	+92.97%	767.17Cr
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD.	+0.48%	-3.09%	-46.17%	-71.45%	407.37Cr
DOUBLE MEDICAL TECHNOLOGY INC.	+1.51%	+0.28%	+19.85%	+35.05%	255.6Cr
BEIJING BALANCE MEDICAL TECHNOLOGY CO.,LTD.	+0.94%	-1.24%	-13.34%	-15.72%	177.59Cr
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD.	-0.21%	-4.06%	+3.70%	-20.10%	159.42Cr
L&C BIO CO.,LTD	+5.36%	+9.88%	+200.71%	+151.86%	140.78Cr
Average	-0.35%	+0.99%	+22.46%	+20.96%	1.87TCr
Weighted average by Cap.	+1.91%	+0.73%	-11.14%	+7.24%

	2023	2024
Net sales	4.29Cr 44.76L 39.03L 36.15L 33.84L 63.46L 42Cr 63.84L 1.66Cr 21Cr 1.68Cr 1.64Cr 72Cr	5.8Cr 60.53L 52.77L 48.88L 45.76L 85.81L 57Cr 86.33L 2.25Cr 28Cr 2.27Cr 2.22Cr 98Cr
Net income	-21Cr -2.18Cr -1.9Cr -1.76Cr -1.65Cr -3.09Cr -205.74Cr -3.11Cr -8.1Cr -101.27Cr -8.18Cr -8.01Cr -351.63Cr	-9.6Cr -1Cr -87.36L -80.91L -75.74L -1.42Cr -95Cr -1.43Cr -3.72Cr -47Cr -3.76Cr -3.68Cr -161.58Cr
Net Debt	4.38Cr 45.77L 39.91L 36.96L 34.6L 64.89L 43Cr 65.28L 1.7Cr 21Cr 1.72Cr 1.68Cr 74Cr	21Cr 2.23Cr 1.95Cr 1.8Cr 1.69Cr 3.16Cr 210.57Cr 3.18Cr 8.29Cr 103.65Cr 8.38Cr 8.2Cr 359.89Cr